- Home
- HDL vs GYRE Comparison
HDL vs GYRE Comparison
Compare HDL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- GYRE
- Stock Information
- Founded
- HDL 2016
- GYRE 2002
- Country
- HDL Singapore
- GYRE United States
- Employees
- HDL N/A
- GYRE N/A
- Industry
- HDL Restaurants
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- GYRE Health Care
- Exchange
- HDL Nasdaq
- GYRE Nasdaq
- Market Cap
- HDL 1.2B
- GYRE 1.1B
- IPO Year
- HDL 2024
- GYRE N/A
- Fundamental
- Price
- HDL $24.62
- GYRE $9.99
- Analyst Decision
- HDL
- GYRE
- Analyst Count
- HDL 0
- GYRE 0
- Target Price
- HDL N/A
- GYRE N/A
- AVG Volume (30 Days)
- HDL 17.1K
- GYRE 141.0K
- Earning Date
- HDL 02-20-2025
- GYRE 11-13-2024
- Dividend Yield
- HDL N/A
- GYRE N/A
- EPS Growth
- HDL N/A
- GYRE N/A
- EPS
- HDL 0.09
- GYRE N/A
- Revenue
- HDL $759,894,000.00
- GYRE $105,033,000.00
- Revenue This Year
- HDL $18.96
- GYRE $25.32
- Revenue Next Year
- HDL $14.25
- GYRE $12.95
- P/E Ratio
- HDL $28.37
- GYRE N/A
- Revenue Growth
- HDL 16.09
- GYRE N/A
- 52 Week Low
- HDL $13.94
- GYRE $8.26
- 52 Week High
- HDL $30.00
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- GYRE 41.39
- Support Level
- HDL N/A
- GYRE $9.59
- Resistance Level
- HDL N/A
- GYRE $10.58
- Average True Range (ATR)
- HDL 0.00
- GYRE 0.97
- MACD
- HDL 0.00
- GYRE -0.15
- Stochastic Oscillator
- HDL 0.00
- GYRE 9.76
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.